Objective. To assess the pharmacokinetics (PK) and safety profile of aliskiren in pediatric patients (6-17 years old) with hypertension. Methods. Patients were randomized to a single weight-based dose of either 2 mg/kg (n = 19) or 6 mg/kg (n = 20) of aliskiren daily for 8 days. The PK, pharmacodynamics, safety profile, and efficacy of aliskiren were assessed. Results. Of the 39 randomized patients, 37 (94.9%) completed the study. Aliskiren plasma concentration (maximum plasma concentration and area under the plasma concentration–time curve) increased dose dependently, achieving peak concentrations in 1 to 2 hours, and tmax was comparable across the dose and age groups. Treatment-emergent adverse events (AEs) were reported in 18 (46.2%) patients, with headache, abdominal pain, and nausea being the most frequent. Conclusions. Aliskiren 2 mg/kg and 6 mg/kg daily showed dose-dependent increases in the plasma concentration. The drug was well tolerated in hypertensive children aged 6 to 17 years. AEs were generally mild and not related to either the drug or the dose.
LewingtonSClarkeRQizilbashNPetoRCollinsR. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
2.
OgdenCLFlegalKMCarrollMDJohnsonCL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 2002;288:1728-1732.
3.
The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-576.
4.
LurbeECifkovaRCruickshankJK. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719-1742.
5.
ChobanianAVBakrisGLBlackHR. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
6.
EpsteinBJ. Aliskiren and valsartan combination therapy for the management of hypertension. Vasc Health Risk Manag. 2010;6:711-722.
7.
KellyDJZhangYMoeGNaikGGilbertRE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007;50:2398-2404.
8.
WeirMRBushCAndersonDRZhangJKeefeDSatlinA. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens. 2007;1:264-277.
9.
VaidyanathanSJermanyJYehCBizotMNCamisascaR. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol. 2006;62:690-698.
10.
WilliamsBPoulterNRBrownMJ. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004;18:139-185.
11.
SmithBPVandenhendeFRDeSanteKA. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17:1278-1283.
12.
AziziMMenardJBisseryA. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126-3133.
13.
NussbergerJWuerznerGJensenCBrunnerHR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1-E8.
14.
VaidyanathanSLimogesDYehC. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 2005;79:P64.
15.
ZhaoCVaidyanathanSYehCMMaboudianMArminDH. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2006;45:1125-1134.
16.
LimogesDDieterichHAYehCMVaidyanathanSHowardDDoleWP. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther. 2008;46:252-258.
17.
HuPBartlettMKaranRS. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study. Clin Drug Investig. 2010;30:221-228.
18.
VaidyanathanSJarugulaVDieterichHAHowardDDoleWP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47: 515-531.
19.
DugganSTChwiedukCMCurranMP. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension. Drugs. 2010;70:2011-2049.
